Trial Profile
A Phase II Randomised Pilot Study to Compare the Efficacy and Safety of Subcutaneous, Bioresorbable Afamelanotide Implants and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Apr 2014
Price :
$35
*
At a glance
- Drugs Afamelanotide (Primary)
- Indications Vitiligo
- Focus Therapeutic Use
- Sponsors Clinuvel Pharmaceuticals
- 17 Apr 2014 New trial record